Geulah Livshits
Stock Analyst at Chardan Capital
(3.17)
# 1,071
Out of 4,906 analysts
202
Total ratings
38.31%
Success rate
3.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $25 | $4.24 | +489.62% | 10 | Jul 3, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 | $65.33 | +25.52% | 14 | Jun 26, 2025 | |
| PASG Passage Bio | Maintains: Buy | $120 | $5.27 | +2,177.04% | 5 | Jun 24, 2025 | |
| IMRX Immuneering | Maintains: Buy | $13 | $4.24 | +206.60% | 12 | Jun 18, 2025 | |
| SNTI Senti Biosciences | Maintains: Buy | $12 | $2.01 | +497.01% | 9 | Jun 12, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $7 → $9 | $2.53 | +256.44% | 13 | May 29, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $46 → $17 | $3.13 | +443.13% | 18 | May 28, 2025 | |
| PRME Prime Medicine | Maintains: Buy | $16 → $12 | $4.57 | +162.58% | 5 | May 19, 2025 | |
| SLDB Solid Biosciences | Maintains: Buy | $16 → $15 | $6.37 | +135.48% | 7 | May 19, 2025 | |
| IPSC Century Therapeutics | Maintains: Buy | $7 → $6 | $0.58 | +943.48% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $12 | $2.17 | +453.00% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $20 | $3.95 | +406.97% | 9 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $25 | $2.49 | +904.02% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 | $12.63 | +438.40% | 14 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $0.86 | +950.67% | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $219 | $147.72 | +48.25% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $31.00 | +61.29% | 1 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.53 | - | 3 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.15 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $8.66 | +373.44% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $25 | $5.82 | +329.55% | 2 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.64 | +631.71% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $30.97 | +571.62% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $1.15 | +1,297.38% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $8.49 | +960.07% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $3.17 | +26.18% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $2.69 | +1,015.24% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $10.82 | +66.36% | 1 | Oct 27, 2020 |
4D Molecular Therapeutics
Jul 3, 2025
Maintains: Buy
Price Target: $25
Current: $4.24
Upside: +489.62%
CRISPR Therapeutics AG
Jun 26, 2025
Maintains: Buy
Price Target: $82
Current: $65.33
Upside: +25.52%
Passage Bio
Jun 24, 2025
Maintains: Buy
Price Target: $120
Current: $5.27
Upside: +2,177.04%
Immuneering
Jun 18, 2025
Maintains: Buy
Price Target: $13
Current: $4.24
Upside: +206.60%
Senti Biosciences
Jun 12, 2025
Maintains: Buy
Price Target: $12
Current: $2.01
Upside: +497.01%
Taysha Gene Therapies
May 29, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $2.53
Upside: +256.44%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Buy
Price Target: $46 → $17
Current: $3.13
Upside: +443.13%
Prime Medicine
May 19, 2025
Maintains: Buy
Price Target: $16 → $12
Current: $4.57
Upside: +162.58%
Solid Biosciences
May 19, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $6.37
Upside: +135.48%
Century Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.58
Upside: +943.48%
May 15, 2025
Maintains: Buy
Price Target: $13 → $12
Current: $2.17
Upside: +453.00%
May 13, 2025
Maintains: Buy
Price Target: $22 → $20
Current: $3.95
Upside: +406.97%
May 9, 2025
Maintains: Buy
Price Target: $30 → $25
Current: $2.49
Upside: +904.02%
May 9, 2025
Maintains: Buy
Price Target: $68
Current: $12.63
Upside: +438.40%
May 9, 2025
Maintains: Buy
Price Target: $9
Current: $0.86
Upside: +950.67%
May 7, 2025
Maintains: Buy
Price Target: $219
Current: $147.72
Upside: +48.25%
Apr 9, 2025
Initiates: Buy
Price Target: $50
Current: $31.00
Upside: +61.29%
Jan 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.53
Upside: -
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.15
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $8.66
Upside: +373.44%
Mar 23, 2023
Maintains: Buy
Price Target: $28 → $25
Current: $5.82
Upside: +329.55%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $1.64
Upside: +631.71%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $30.97
Upside: +571.62%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $1.15
Upside: +1,297.38%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $8.49
Upside: +960.07%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $3.17
Upside: +26.18%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $2.69
Upside: +1,015.24%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $10.82
Upside: +66.36%